Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H12N2O2S |
Molecular Weight | 248.3024 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1cc(ccc1N)S(=O)(=O)c2ccc(cc2)N
InChI
InChIKey=MQJKPEGWNLWLTK-UHFFFAOYSA-N
InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
DescriptionSources: http://escholarship.org/uc/item/30m4b5krCurator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021794s000_MicroR.pdf
Sources: http://escholarship.org/uc/item/30m4b5kr
Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021794s000_MicroR.pdf
Dapsone was synthesized in 1908 by Fromm and Wittmann. The drug was approved by FDA for the treatment of such conditions as acne vulgaris, leprosy and dermatitis herpetiformis, also the drug is used off-label for many skin diseases. Although the exact mechanism of dapsone action is unknown, it is speculated that it acts as both anti-inflammatory and antimicrobial agent. It was demonstrated that dapsone suppresses ROS generation, inhibits neutrophil myeloperoxidase and eosinophil peroxidase and also inhibits bacterial dihydropteroate synthase.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24310318 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | ACZONE Approved UseGel is indicated for the topical treatment of acne vulgaris. Launch Date-4.73385599E11 |
|||
Curative | DAPSONE Approved UseDermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance. Launch Date2.99807998E11 |
|||
Curative | DAPSONE Approved UseDermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance. Launch Date2.99807998E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1375 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17655376 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
DAPSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
19.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17655376 |
110 mg 2 times / day steady-state, topical dose: 110 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
DAPSONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
221.52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17655376 |
110 mg 2 times / day steady-state, topical dose: 110 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
DAPSONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
22783 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17655376 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
DAPSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
415 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17655376 |
110 mg 2 times / day steady-state, topical dose: 110 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
DAPSONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
52641 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17655376 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
DAPSONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17655376 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
DAPSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
42 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17655376 |
110 mg 2 times / day steady-state, topical dose: 110 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
DAPSONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% |
unknown, unknown |
DAPSONE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
300 mg 1 times / week multiple, oral Highest studied dose Dose: 300 mg, 1 times / week Route: oral Route: multiple Dose: 300 mg, 1 times / week Sources: Page: p.1582 |
unhealthy, 38 n = 9 Health Status: unhealthy Condition: Pneumocystis pneumonia Age Group: 38 Sex: M+F Population Size: 9 Sources: Page: p.1582 |
Disc. AE: Anemia, Rash... AEs leading to discontinuation/dose reduction: Anemia (11.1%) Sources: Page: p.1582Rash (11.1%) Fever (11.1%) |
200 mg 1 times / week multiple, oral MTD Dose: 200 mg, 1 times / week Route: oral Route: multiple Dose: 200 mg, 1 times / week Sources: Page: p.1582 |
unhealthy, 38 n = 7 Health Status: unhealthy Condition: Pneumocystis pneumonia Age Group: 38 Sex: M+F Population Size: 7 Sources: Page: p.1582 |
Disc. AE: Vomiting, Fever... AEs leading to discontinuation/dose reduction: Vomiting (14.3%) Sources: Page: p.1582Fever (14.3%) |
10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: Page: p.216 |
unhealthy, 45 n = 1 Health Status: unhealthy Condition: Dermatitis herpatiformis Age Group: 45 Sex: M Population Size: 1 Sources: Page: p.216 |
Disc. AE: Cyanosis, Methaemoglobinaemia... AEs leading to discontinuation/dose reduction: Cyanosis (acute) Sources: Page: p.216Methaemoglobinaemia Haemolysis |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anemia | 11.1% Disc. AE |
300 mg 1 times / week multiple, oral Highest studied dose Dose: 300 mg, 1 times / week Route: oral Route: multiple Dose: 300 mg, 1 times / week Sources: Page: p.1582 |
unhealthy, 38 n = 9 Health Status: unhealthy Condition: Pneumocystis pneumonia Age Group: 38 Sex: M+F Population Size: 9 Sources: Page: p.1582 |
Fever | 11.1% Disc. AE |
300 mg 1 times / week multiple, oral Highest studied dose Dose: 300 mg, 1 times / week Route: oral Route: multiple Dose: 300 mg, 1 times / week Sources: Page: p.1582 |
unhealthy, 38 n = 9 Health Status: unhealthy Condition: Pneumocystis pneumonia Age Group: 38 Sex: M+F Population Size: 9 Sources: Page: p.1582 |
Rash | 11.1% Disc. AE |
300 mg 1 times / week multiple, oral Highest studied dose Dose: 300 mg, 1 times / week Route: oral Route: multiple Dose: 300 mg, 1 times / week Sources: Page: p.1582 |
unhealthy, 38 n = 9 Health Status: unhealthy Condition: Pneumocystis pneumonia Age Group: 38 Sex: M+F Population Size: 9 Sources: Page: p.1582 |
Fever | 14.3% Disc. AE |
200 mg 1 times / week multiple, oral MTD Dose: 200 mg, 1 times / week Route: oral Route: multiple Dose: 200 mg, 1 times / week Sources: Page: p.1582 |
unhealthy, 38 n = 7 Health Status: unhealthy Condition: Pneumocystis pneumonia Age Group: 38 Sex: M+F Population Size: 7 Sources: Page: p.1582 |
Vomiting | 14.3% Disc. AE |
200 mg 1 times / week multiple, oral MTD Dose: 200 mg, 1 times / week Route: oral Route: multiple Dose: 200 mg, 1 times / week Sources: Page: p.1582 |
unhealthy, 38 n = 7 Health Status: unhealthy Condition: Pneumocystis pneumonia Age Group: 38 Sex: M+F Population Size: 7 Sources: Page: p.1582 |
Haemolysis | Disc. AE | 10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: Page: p.216 |
unhealthy, 45 n = 1 Health Status: unhealthy Condition: Dermatitis herpatiformis Age Group: 45 Sex: M Population Size: 1 Sources: Page: p.216 |
Methaemoglobinaemia | Disc. AE | 10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: Page: p.216 |
unhealthy, 45 n = 1 Health Status: unhealthy Condition: Dermatitis herpatiformis Age Group: 45 Sex: M Population Size: 1 Sources: Page: p.216 |
Cyanosis | acute Disc. AE |
10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: Page: p.216 |
unhealthy, 45 n = 1 Health Status: unhealthy Condition: Dermatitis herpatiformis Age Group: 45 Sex: M Population Size: 1 Sources: Page: p.216 |
PubMed
Title | Date | PubMed |
---|---|---|
Erythema nodosum leprosum in Nigeria. | 1975 Nov |
|
Dapsone-induced motor polyneuropathy. A complication of prolonged treatment of subcorneal pustular dermatosis. | 1976 Aug |
|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Management difficulties due to concurrent dermatitis herpetiformis and variegate porphyria. | 2000 Sep |
|
[Hypersensitivity syndrome and HHV-6]. | 2001 Nov |
|
Immunohematotoxicity studies with combinations of dapsone and zidovudine. | 2001 Nov |
|
Dapsone-induced cholestasis and impairment of bile salt output in the rat. | 2002 Apr 15 |
|
Vitamin E for dapsone-induced headache. | 2002 Jan |
|
Dapsone. | 2002 Jun |
|
Bioavailability factors of isoniazid in fast and slow acetylators, healthy volunteers. | 2002 Nov-Dec |
|
Unfolding of phonetic information over time: a database of Dutch diphone perception. | 2003 Jan |
|
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. | 2003 Sep |
|
Monitoring of ELISA for anti-BP180 antibodies: clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid. | 2004 May |
|
Dapsone syndrome with acute renal failure during leprosy treatment: case report. | 2005 Feb |
|
Relationships between nonword repetition accuracy and other measures of linguistic development in children with phonological disorders. | 2005 Feb |
|
Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy. | 2005 Jun |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Protective role of vitamin E on the oxidative stress in Hansen's disease (Leprosy) patients. | 2005 Oct |
|
The contribution of prosody to the perception of foreign accent. | 2006 |
|
Anterior ischaemic optic neuropathy associated with Dapsone. | 2006 Aug |
|
[Disulone and hepatosiderosis]. | 2006 Aug-Sep |
|
Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. | 2007 Apr 24 |
|
Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. | 2007 Dec |
|
Dapsone induces oxidative stress and impairs antioxidant defenses in rat liver. | 2008 Aug 1 |
|
Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. | 2009 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment:: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fc98c9b-b17a-f66f-055b-259207ad9504
Apply 5% gel to the acne affected areas twice a day (Aczone gel). In dermatitis herpetiformis, the starting oral dose is 50 mg and in leprosy, the dose is 100 mg/day (Dapsone oral formulation).
Route of Administration:
Other
With Staphylococcus aureus (both methicillin-susceptible S. aureus-MSSA and methicillinresistant S. aureus-MRSA), dapsone MIC50, MIC90 were 128 ug/mL and 256 ug/mL, respectively. For Staphylococcus epidermidis overall, dapsone MIC50, MIC90 were 128 ug/mL and 256 ug/mL, respectively. Overall results with Enterococcus faecalis, dapsone MIC50, MIC90 were 256 ug/mL and 512 ug/mL, respectively. With Streptococcus agalactiae, dapsone MIC50, MIC90 were reported overall to be 32 ug/mL and 256 ug/mL, respectively. For Streptococcus pyogenes, dapsone MIC50, MIC90 were 32 ug/mL and 512 ug/mL, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000008053
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
NCI_THESAURUS |
C849
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
WHO-VATC |
QD10AX05
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.3
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
WHO-ATC |
J04BA02
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
WHO-VATC |
QJ04BA02
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
WHO-ATC |
D10AX05
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
FDA ORPHAN DRUG |
85694
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
NDF-RT |
N0000175881
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
NDF-RT |
N0000008053
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
FDA ORPHAN DRUG |
61291
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
EPA PESTICIDE CODE |
690107
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
LIVERTOX |
264
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
||
|
FDA ORPHAN DRUG |
61191
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5073
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
D003622
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
2955
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
SUB06909MIG
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
CHEMBL1043
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
8W5C518302
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
80-08-0
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
3108
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | RxNorm | ||
|
782
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
201-248-4
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
M4092
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | Merck Index | ||
|
1164008
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | USP-RS | ||
|
1676
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
DAPSONE
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | Description: A white or creamy white, crystalline powder; odourless. Solubility: Soluble in 7000 parts of water and in 30 parts of ethanol (~750 g/l) TS; soluble in acetone R.Category: Antileprotic. Storage: Dapsone should be kept in a tightly closed container, protected from light. Additional information: Even in the absence of light, Dapsone is gradually degraded on exposure to a humid atmosphere, thedecomposition being faster at higher temperatures. | ||
|
DAPSONE
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
Dapsone
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
DB00250
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
C415
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY | |||
|
80-08-0
Created by
admin on Fri Jun 25 20:55:45 UTC 2021 , Edited by admin on Fri Jun 25 20:55:45 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE TOXIC (PARENT)